EUVIMEDSkopri EUVIMED
Crossref

Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients

Elaine Ku iD, Erica Winnicki, Sabrina Legaspi, Feng Lin, Charles E McCulloch, Deborah Adey

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70443 ↗

At a glance

Journal article in Clinical Transplantation, 2026. Written by Elaine Ku and 5 co-authors. Institution: Department of Medicine, University of California San Francisco, San Francisco, California, USA. Major MEDLINE topics: Kidney Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Kidney Failure, Chronic. 18 references. Funded by: Natera.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The gold standard approach to the diagnosis of rejection in kidney transplant recipients currently relies on tissue obtained during biopsies. However, repeat performance of biopsies is cumbersome, and use of dd‐cfDNA in conjunction with eGFR may help inform whether ongoing rejection may be persistent after a diagnosis of rejection is made by biopsy and anti‐rejection treatment administered. In this single‐center prospective study, 52 patients with rejection were followed longitudinally over time with quarterly dd‐cfDNA measurements, of whom 78% had repeat biopsies to confirm the presence or absence of persistent rejection. With every 1 percentage point higher baseline (“first”) dd‐cfDNA levels drawn at time of enrollment, the odds of persistent rejection were 1.35 (95% CI 1.18‐1.55) higher. With every 1 percentage point increase in the slope of dd‐cfDNA levels over time, the odds of persistent rejection were 1.62 times higher (95% CI 1.10‐2.38). Models including only baseline and the slope of dd‐cfDNA provided moderate risk discrimination for rejection (c = 0.73), which improved to c = 0.75 with the addition of eGFR at baseline and change in eGFR over time. Monitoring of dd‐cfDNA may offer reasonable discrimination of the likelihood of persistent rejection following anti‐rejection therapy. Further validation of these findings is needed.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationGraft RejectionCell-Free Nucleic AcidsKidney Failure, ChronicTissue DonorsBiomarkersHumansFemaleProspective StudiesFollow-Up StudiesPrognosisMaleGlomerular Filtration RateMiddle AgedKidney Function TestsGraft SurvivalAdultRisk FactorsTransplant Recipients

Author keywords

Cell free DNAkidney transplantrejection

Substances

Cell-Free Nucleic AcidsBiomarkers

Authors and institutions

  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

ORCID profiles: Elaine Ku

Funding

  • Natera

Cite

APA

Ku, E., Winnicki, E., Legaspi, S., Lin, F., McCulloch, C. E., & Adey, D. (2026). Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70443

Vancouver

Ku E, Winnicki E, Legaspi S, Lin F, McCulloch CE, Adey D. Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients. Clinical Transplantation. 2026. doi:10.1111/ctr.70443

BibTeX
@article{Ku2026,
  author = {Ku, Elaine and Winnicki, Erica and Legaspi, Sabrina and Lin, Feng and McCulloch, Charles E and Adey, Deborah},
  title = {Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70443}
}
Start for free →